Ocugen, Inc. develops gene therapies for blindness diseases through a modifier gene therapy platform designed to address inherited and multifactorial retinal disorders. Company news commonly covers programs such as OCU400 for retinitis pigmentosa, OCU410 for geographic atrophy secondary to dry age-related macular degeneration, and OCU410ST for Stargardt disease.
Recurring updates include clinical trial data and dosing milestones, clinical and regulatory disclosures, operating and financial results, investor presentations, convertible-note financing, shareholder voting matters, capital-structure actions, and governance matters tied to the company's Nasdaq-listed common stock.
Ocugen (NASDAQ: OCGN) has secured exclusive co-development, manufacturing, and commercialization rights for COVAXIN™ in Canada, enhancing its existing rights in the U.S. This expansion underscores the company’s strategic partnership with Bharat Biotech, as they aim to submit applications for emergency use authorization in both countries. Ocugen will share profits from COVAXIN™ sales in Canada, retaining 45%. COVAXIN™ has shown a 78% overall efficacy rate and demonstrated effectiveness against multiple SARS-CoV-2 variants, with an excellent safety record.
Ocugen (NASDAQ: OCGN) announced plans to submit an Emergency Use Authorization (EUA) application for its COVID-19 vaccine, COVAXIN, to the FDA in June. Active discussions with the FDA have been ongoing since late last year, and the company expressed confidence in meeting the updated EUA criteria. COVAXIN is a traditional inactivated vaccine that has shown a 78% efficacy rate overall and is 100% effective against severe COVID-19 in Phase 3 trials. It demonstrates potential effectiveness against multiple SARS-CoV-2 variants, with a strong safety profile.
Ocugen reported promising updates regarding its COVID-19 vaccine COVAXIN and its ophthalmology pipeline. COVAXIN showed 100% efficacy against severe COVID-19 and a 78% overall efficacy in trials. The company raised $100 million through a direct stock offering, strengthening its financial position. Key talent was recruited to enhance manufacturing capabilities for COVAXIN. As of March 31, 2021, Ocugen's cash totaled $44.9 million, while R&D expenses increased to $2.9 million. A conference call is scheduled for today to discuss these results.
Ocugen has presented promising pre-clinical data for OCU200, a transferrin-tumstatin fusion protein, targeting ocular neovascular diseases such as Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), and Wet-AMD. The study shows OCU200's efficacy in reducing retinal damage and neovascularization, demonstrating comparable activity to aflibercept in animal models. Key findings include a 68% reduction in avascular areas and significant reduction in neovascular tufts. The data was presented at the ARVO 2021 Annual Meeting.
Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical firm, announced it will host a conference call on May 7, 2021, at 8:30 a.m. ET to discuss first-quarter 2021 financial results and provide a business update. A pre-market earnings announcement will precede the call. The company focuses on gene therapies for blindness and co-developing Bharat Biotech's COVAXIN™ COVID-19 vaccine for the U.S. market. Investors can access the call via dial-in or webcast, which will be archived for 45 days.
Ocugen (NASDAQ: OCGN) announced promising results for its COVID-19 vaccine candidate, COVAXIN. A study by the Indian Council of Medical Research revealed COVAXIN's efficacy against multiple SARS-CoV-2 variants, including the Brazil variant (B.1.128.2) and the double mutant variant (B.1.617). COVAXIN demonstrated 78% overall efficacy and 100% efficacy against severe COVID-19. The company is preparing an Emergency Use Authorization application with the FDA and highlighted the vaccine's strong immune response and safety profile.
Ocugen, Inc. (Nasdaq: OCGN) has completed a registered direct offering, selling 10 million shares at $10 per share, raising approximately $100 million before expenses. The offering, facilitated by H.C. Wainwright & Co., aims to fund general corporate expenses and working capital. The shares were registered under an automatic shelf registration statement. This strategic move positions Ocugen to further its mission in gene therapies for blindness and COVID-19 vaccine development, highlighting its commitment to innovation in biopharmaceuticals.
Ocugen announced a registered direct offering of 10 million shares of common stock at $10 per share, aiming for $100 million in gross proceeds. The offering, managed by H.C. Wainwright & Co., is expected to close around April 27, 2021. Ocugen plans to use the funds for general corporate purposes, capital expenditures, and working capital. The shares will be offered under an effective shelf registration statement filed with the SEC.
Ocugen (NASDAQ: OCGN) announced promising results from Bharat Biotech's Phase 3 trial of COVAXIN, indicating a vaccine efficacy of 78% against COVID-19 after two doses. Notably, it showcased 100% efficacy against severe COVID-19 cases and 70% efficacy against asymptomatic infections. The trial involved 25,800 participants, with recent data reflecting 127 symptomatic cases leading to these positive outcomes. COVAXIN has already been administered to millions in India, underlining its critical role in pandemic control.
Ocugen (NASDAQ: OCGN) announced the appointment of John Paul (J.P.) Gabriel as Senior Vice President of Manufacturing and Supply Chain. With over 25 years of experience, Gabriel has held key roles in leading biopharmaceutical companies, including Sanofi Pasteur and Pfizer Vaccines. His expertise will be vital in facilitating the U.S. manufacturing of COVAXIN, a COVID-19 vaccine candidate co-developed by Ocugen. Gabriel is expected to contribute significantly to the technology transfer from Bharat Biotech, enhancing Ocugen's capabilities in the vaccine sector.